Bevacizumab at a dose of 7.5mg/Kg [BEV10]

As MAINTENANCE monotherapy for patients with stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma where the following criteria have been met: Note: there is a separate form BEV3 for the use of bevacizumab at a dose of 7.5mg/Kg in combination with 1st line chemotherapy AS INDUCTION TREATMENT for advanced ovarian cancer Note: there is a separate form BEV9 for the use of bevacizumab at a dose of 15mg/Kg in combination with 1st line chemotherapy AS INDUCTION TREATMENT for advanced ovarian cancer Note: if an application is being made for the 1st line maintenance combination

  1. I confirm that this application is being made by and the first cycle of systemic anti-cancer therapy with maintenance bevacizumab monotherapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
  2. I confirm that bevacizumab at a dose of 7.5mg/Kg is to be used as maintenance monotherapy after completion of 1st line induction chemotherapy in combination with bevacizumab 7.5mg/Kg for previously untreated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
  3. I confirm that this application for maintenance bevacizumab monotherapy continues the use of bevacizumab 7.5mg/Kg previously given in combination with 1st line induction chemotherapy.
  4. I confirm that bevacizumab is to be given as monotherapy for a maximum of 18 cycles in all, this figure including the number of cycles given in combination with 1st line induction chemotherapy.
  5. I confirm that bevacizumab is to be given at a dose of 7.5mg/Kg every 3 weeks.
  6. I confirm that I understand that this dosage of bevacizumab is not licensed in ovarian cancer, this use of bevacizumab must be used within the treating Trust’s governance framework. Note: This policy relating to the use of maintenance bevacizumab 7.5mg/Kg is NOT for patients with stage I-III disease who have had optimal debulking
  7. I confirm that when a treatment break is needed of more than 6 weeks beyond the expected cycle length of 3-weekly treatment, I will complete a treatment break approval form to restart treatment, including as appropriate if the patient had an extended break on account of Covid-19.
  8. I confirm that bevacizumab is to be otherwise used as set out in its Summary of Product Characteristics. of

[NHS funded]{.badge .rounded-pill .bg-success} From: 01 April 2021

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: - NHS England clinical policy (NA)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.